Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Cellular Immunology|July 1, 1984
Natural killer-like function of activated T lymphocytes: differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structureT Hercend, S Meuer, A Brennan, et al.
The Journal of Experimental Medicine|September 1, 1986
Sequences and diversity of human T cell receptor beta chain variable region genesN Kimura, B Toyonaga, Y Yoshikai, et al.
Experimental Hematology|July 1, 1979
Trochanter bone marrow: a source of normal human colony forming cellsP G de Laforest, B Rio, F Triebel, et al.
The Journal of Experimental Medicine|November 1, 1983
Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector functionT Hercend, S Meuer, A Brennan, et al.
Transplantation|September 1, 1986
Characterization of antileukemia cells' cytotoxic effector function. Implications for monitoring natural killer responses following allogeneic bone marrow transplantationL Delmon, A Ythier, P Moingeon, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1983
Interleukin-2 production after blood transfusions in prospective kidney transplant recipientsJ C Gluckman, D Klatzmann, F Triebel, et al.
International Journal of Cancer|February 15, 1986
Media conditioned by human leukemic T-cells induce expression of IL2 receptors and proliferation of normal T lymphocytesC Kosmatopoulos, M Allouche, F Triebel, et al.
The Journal of Experimental Medicine|June 1, 1986
Natural killer clones derived from fetal (25 wk) blood. Probing the human T cell receptor with WT31 monoclonal antibodyA Nowill, P Moingeon, A Ythier, et al.
The Journal of Experimental Medicine|November 1, 1994
Surface expression of functional T cell receptor chains formed by interlocus recombination on human T lymphocytesF Davodeau, M A Peyrat, J Gaschet, et al.
Bulletin Du Cancer|April 1, 1995
[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute]B Escudier, F Farace, C Théodore, et al.
Pageof 17